Advanced search
1 file | 2.55 MB Add to list

In vitro and ex vivo delivery of tailored siRNA-nanoliposomes for E2F1 silencing as a potential therapy for colorectal cancer

Author
Organization
Keywords
Nanoliposome, siRNA delivery, E2F1, Colonic mucosa, Colorectal cancer, INFLAMMATORY-BOWEL-DISEASE, HEPATOCELLULAR-CARCINOMA, TRANSCRIPTION FACTOR, CATIONIC LIPOSOMES, DOWN-REGULATION, THERAPEUTICS, NANOPARTICLES, CARRIERS, CIRCUIT, SYSTEMS

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 2.55 MB

Citation

Please use this url to cite or link to this publication:

MLA
Bochicchio, Sabrina et al. “In Vitro and Ex Vivo Delivery of Tailored siRNA-nanoliposomes for E2F1 Silencing as a Potential Therapy for Colorectal Cancer.” INTERNATIONAL JOURNAL OF PHARMACEUTICS 525.2 (2017): 377–387. Print.
APA
Bochicchio, S., Dapas, B., Russo, I., Ciacci, C., Piazza, O., De Smedt, S., Pottie, E., et al. (2017). In vitro and ex vivo delivery of tailored siRNA-nanoliposomes for E2F1 silencing as a potential therapy for colorectal cancer. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 525(2), 377–387.
Chicago author-date
Bochicchio, Sabrina, Barbara Dapas, Ilaria Russo, Carolina Ciacci, Ornella Piazza, Stefaan De Smedt, Eline Pottie, Anna Angela Barba, and Gabriele Grassi. 2017. “In Vitro and Ex Vivo Delivery of Tailored siRNA-nanoliposomes for E2F1 Silencing as a Potential Therapy for Colorectal Cancer.” International Journal of Pharmaceutics 525 (2): 377–387.
Chicago author-date (all authors)
Bochicchio, Sabrina, Barbara Dapas, Ilaria Russo, Carolina Ciacci, Ornella Piazza, Stefaan De Smedt, Eline Pottie, Anna Angela Barba, and Gabriele Grassi. 2017. “In Vitro and Ex Vivo Delivery of Tailored siRNA-nanoliposomes for E2F1 Silencing as a Potential Therapy for Colorectal Cancer.” International Journal of Pharmaceutics 525 (2): 377–387.
Vancouver
1.
Bochicchio S, Dapas B, Russo I, Ciacci C, Piazza O, De Smedt S, et al. In vitro and ex vivo delivery of tailored siRNA-nanoliposomes for E2F1 silencing as a potential therapy for colorectal cancer. INTERNATIONAL JOURNAL OF PHARMACEUTICS. 2017;525(2):377–87.
IEEE
[1]
S. Bochicchio et al., “In vitro and ex vivo delivery of tailored siRNA-nanoliposomes for E2F1 silencing as a potential therapy for colorectal cancer,” INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 525, no. 2, pp. 377–387, 2017.
@article{8539165,
  author       = {Bochicchio, Sabrina and Dapas, Barbara and Russo, Ilaria and Ciacci, Carolina and Piazza, Ornella and De Smedt, Stefaan and Pottie, Eline and Barba, Anna Angela and Grassi, Gabriele},
  issn         = {0378-5173},
  journal      = {INTERNATIONAL JOURNAL OF PHARMACEUTICS},
  keywords     = {Nanoliposome,siRNA delivery,E2F1,Colonic mucosa,Colorectal cancer,INFLAMMATORY-BOWEL-DISEASE,HEPATOCELLULAR-CARCINOMA,TRANSCRIPTION FACTOR,CATIONIC LIPOSOMES,DOWN-REGULATION,THERAPEUTICS,NANOPARTICLES,CARRIERS,CIRCUIT,SYSTEMS},
  language     = {eng},
  number       = {2},
  pages        = {377--387},
  title        = {In vitro and ex vivo delivery of tailored siRNA-nanoliposomes for E2F1 silencing as a potential therapy for colorectal cancer},
  url          = {http://dx.doi.org/10.1016/j.ijpharm.2017.02.020},
  volume       = {525},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: